Cargando…
Eculizumab Dosing in Infants
Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more preci...
Autores principales: | Kobrzynski, M., Wile, B., Huang, S. S., Filler, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830814/ https://www.ncbi.nlm.nih.gov/pubmed/29515306 http://dx.doi.org/10.4103/ijn.IJN_310_16 |
Ejemplares similares
-
Successful Treatment of Multiple Angiomyolipomas with Sirolimus in a Child
por: Pabedinskas, K., et al.
Publicado: (2017) -
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
por: Gatault, Philippe, et al.
Publicado: (2015) -
Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020) -
Eculizumab: COVID-19: case report
Publicado: (2021) -
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report
por: Füreder, Wolfgang, et al.
Publicado: (2020)